Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-cash Items (2021 - 2025)

Atara Biotherapeutics filings provide 5 years of Non-cash Items readings, the most recent being $23000.0 for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 14.81% to $23000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $23000.0, a 14.81% decrease, with the full-year FY2025 number at $23000.0, down 86.67% from a year prior.
  • Non-cash Items hit $23000.0 in Q4 2025 for Atara Biotherapeutics, up from $14000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $35.7 million in Q1 2023 to a low of $14000.0 in Q3 2025.
  • Median Non-cash Items over the past 5 years was $4.0 million (2022), compared with a mean of $10.9 million.
  • Biggest five-year swings in Non-cash Items: soared 25334.78% in 2023 and later crashed 99.8% in 2025.
  • Atara Biotherapeutics' Non-cash Items stood at $12.8 million in 2021, then plummeted by 99.67% to $42000.0 in 2022, then surged by 55614.29% to $23.4 million in 2023, then tumbled by 99.88% to $27000.0 in 2024, then fell by 14.81% to $23000.0 in 2025.
  • The last three reported values for Non-cash Items were $23000.0 (Q4 2025), $14000.0 (Q3 2025), and $400000.0 (Q2 2025) per Business Quant data.